Drug Profile
Domagrozumab - Pfizer
Alternative Names: PF 6252616; PF-06252616Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Kennedy Krieger Institute; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy; Limb girdle muscular dystrophies
Most Recent Events
- 28 Sep 2022 Discontinued - Phase-I for Duchenne muscular dystrophy (In volunteers) in USA (SC)
- 28 Sep 2022 Discontinued - Phase-I/II for Limb girdle muscular dystrophies in USA (IV)
- 28 Sep 2022 Discontinued - Phase-II for Duchenne muscular dystrophy (In adolescents, In children) in Canada (IV)